Beta Blockers in Pregnancy and Risk for Fetal Cardiac Anomalies
abstract
This abstract is available on the publisher's site.
Access this abstract nowβ-Blockers are the most commonly used class of medication for treating cardiac conditions in pregnant women. Despite the common use of this class of medication, data that support its safety are limited.
β-Blockers cross the placenta and potentially can cause physiological changes in the fetus. β-Blocker exposure has been shown to cause bradycardia and hypoglycemia in the neonate. A recent meta-analysis reported an association between β-blocker exposure and fetal congenital cardiovascular defects, raising a concern regarding potential teratogenic effects of this class of medication. This study examines the risk of fetal cardiac malformations in association with maternal β-blocker exposure.
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies
JAMA Intern Med 2017 Apr 17;[EPub Ahead of Print], L Duan, A Ng, W Chen, HT Spencer, J Nguyen, AY Shen, MS LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.